Background: Primary hyperoxaluria type 3 (PH3) is due to mutations in the recently identified 4-hydroxy-2-oxoglutarate aldolase (HOGA1) gene. PH3 might be the least severe form with a milder phenotype with good preservation of kidney function in most patients. The aim of this study was to report three PH3 cases carrying mutations in HOGA1.
Materials And Methods: Genetic analysis of HOGA1 was performed in patients with a high clinical suspicion of PH after sequencing of AGXT and GRHPR genes, which was negative. Also, a complete AGXT/GRHPR MLPA was performed in these patients in order to detect large deletions/insertions.
Results And Discussion: Two different HOGA1 gene mutations were identified: the p.Pro190Leu in a homozygous state and the p.Gly287Val in two patients in homozygous and heterozygous carriers. The median age at onset of clinical symptoms was 3.93 years. Most of the patients had a positive family history for recurrent urolithiasis. The p.Pro190Leu mutation was reported with impaired renal function at follow-up; however, the p.Gly287Val was presented with normal renal function. All patients were presented with urolithiasis, but only one had a nephrocalcinosis.
Conclusion: This study expanded the number of PH3 patients from 63 to 66 cases. The p.Pro190Leu and the p.Gly287Val mutations found in this study can provide a first-line investigation in Tunisian PH1 patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6817302 | PMC |
| http://dx.doi.org/10.1002/jcla.22053 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effective Newborn Screening for Type 1 and 3 Primary Hyperoxaluria.
Kidney Int Rep
January 2025
Division of Pediatric Nephrology, Rosenheim Hospital, Germany.
Introduction: Newborn screening (NBS) programs for a defined set of eligible diseases have been enormously successful, but genomic NBS allowing for detection of additional treatable disorders has not been broadly implemented. All 3 types of primary hyperoxaluria (PH1-3) are rare autosomal recessive diseases caused by distinct defects of glyoxylate metabolism that are diagnosed genetically with certainty. Early diagnosis and treatment are mandatory to avoid renal failure or sequalae associated with persistent hyperoxaluria.
View Article and Find Full Text PDFEpidemiological and genetic factors affecting severe epizootic hemorrhagic disease in Spanish Holstein cattle during the Southern Europe outbreak of 2023.
J Dairy Sci
January 2025
Confederación de Asociaciones de Frisona Española (CONAFE), Ctra. de Andalucía km 23600 Valdemoro, 28340 Madrid, Spain.
Epizootic hemorrhagic disease (EHD) is a non-contagious viral infection that can cause important economic losses in dairy farms. This study aimed to identify epidemiological and genetic factors influencing the susceptibility and severity of EHD in Holstein dairy cattle during the 2023 outbreak in Spain. Data from 2852 animals in 7 affected farms from 5 Spanish provinces were used.
View Article and Find Full Text PDFIntegrative analysis of the transcriptome, proteomics and metabolomics reveals key genes involved in the regulation of breast muscle metabolites in capons.
BMC Genomics
December 2024
Guangdong Provincial Key Laboratory of Animal Molecular Design and Precise Breeding, Foshan University, Foshan, 528225, P.R. China.
Castration is widely used in poultry and livestock to enhance fat metabolism and improve the flavor, tenderness and juiciness of meat. However, the genetic regulatory mechanism underlying castration consequences have not been clarified. To investigate the key metabolites affecting the quality of capons and the key regulatory mechanisms, Qingyuan partridge roosters were subjected to castration.
View Article and Find Full Text PDFHuman glyoxylate metabolism revisited: New insights pointing to multi-organ involvement with implications for siRNA-based therapies in primary hyperoxaluria.
J Inherit Metab Dis
January 2025
Department of Pediatric Nephrology, Emma Children's Hospital, Amsterdam, The Netherlands.
Article Synopsis
- - Glyoxylate, a toxic byproduct of metabolism, is rapidly converted into oxalate, necessitating effective detoxification systems in various cell compartments, with key enzymes AGT and GRHPR involved in this process.
- - Mutations in genes encoding AGT and GRHPR lead to primary hyperoxaluria types 1 and 2, respectively, while a defect in the HOGA1 enzyme is associated with type 3, all resulting in serious kidney issues such as nephrocalcinosis and potential kidney failure.
- - Recent advancements in therapies, particularly RNAi-based treatments (lumasiran and nedosiran), are improving outcomes for primary hyperoxaluria, with nedosiran targeting all
Primary hyperoxaluria type 3: from infancy to adulthood in a genetically unique cohort.
Pediatr Nephrol
March 2025
Azrieli Faculty of Medicine, Bar Ilan University, Safed, Israel.
Background: Primary hyperoxaluria type 3 (PH3) is a rare autosomal recessive disorder caused by bi-allelic genetic variants in the 4 hydroxy-2 oxoglutarate aldolase (HOGA-1) gene. We report the natural history of PH3 in a 16-patient cohort, 15 from a unique genetically isolated population.
Methods: This retrospective single-center study followed PH3 patients between 2003 and 2023 with demographic, clinical, radiographic, genetic, and biochemical parameters.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!